NCT05086055

Brief Summary

Multimodal imaging of stroke patients. Patients included in the study will be investigated with multiparametric imaging tools including MRI and EEG imaging. Improvements in motor skills will be monitored clinically.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2021

Typical duration for all trials

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 25, 2021

Completed
5 months until next milestone

First Posted

Study publicly available on registry

October 20, 2021

Completed
22 days until next milestone

Study Start

First participant enrolled

November 11, 2021

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2024

Completed
Last Updated

November 30, 2023

Status Verified

November 1, 2023

Enrollment Period

2.2 years

First QC Date

May 25, 2021

Last Update Submit

November 29, 2023

Conditions

Keywords

Rehabilitation

Outcome Measures

Primary Outcomes (4)

  • Changes in brain volume

    Stroke induced brain volume changes (mm3) will be measured using magnetic resonance imaging (MRI) at 1 day and 6 months post-stroke.

    6 months

  • Stroke induced changes in brain activity.

    Document longitudinal changes in brain activity using EEG. Changes will be measured in cycles/second (Hertz, Hz).

    6 months

  • Changes in inflammatory activity in brain

    Markers of post-stroke inflammation will be measured in pg/ml and ng/ml.

    6 months

  • muscle function

    Longitudinal kinematic profiling. Electromyography measurements of muscle function post-stroke will be measured in cycles/second (Hz) and amplitude (mm). Extension and flexion of arm will be measured in cm. Joint angles will be measured in degrees. Speed of flexion and extension will be measured in cm/second

    6 months

Study Arms (2)

Stroke patients

Stroke patients admitted to the stroke unit, St Olav´s hospital, Trondheim, Norway, without previous stroke, neurological disease or central nervous system (CNS) trauma, will be eligible for inclusion into the study. The planned cohort size is 135 patients.

Behavioral: Kinematic movement analysis

healthy volunteers

Age and gender matched controls without previous CNS disease or trauma are eligible for inclusion into the study. Estimated cohort size is 45 individuals. Volunteers will be recruited through announcement in local newspaper.

Behavioral: Kinematic movement analysis

Interventions

moving arm/leg while registration with electromyography, electroencephalogram, accelerometers, functional near infrared spectroscopy and 3 dimensional video registration of hand, arm, foot and leg movements.

Stroke patientshealthy volunteers

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients 18-years or older of both sexes with subcortical strokes resulting in arm motor deficit, admitted to the stroke unit, St Olav´s Hospital during 2020-2023. All patients admitted to the stroke unit will be scored according to National Institute of Health Score Scale (NIHSS) and the modified Rankin score (mRS) to establish the baseline clinical assessment of neurological dysfunction prior to inclusion

You may qualify if:

  • subcortical strokes resulting in arm motor deficits.
  • admitted to the stroke unit, St Olav´s Hospital during 2021-2023

You may not qualify if:

  • Previous stroke
  • neurodegenerative disease
  • brain tumors
  • previous neurotrauma or brain operation
  • aphasia
  • cognitive dysfunction and claustrophobia preventing MRI examinations.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

OsloMet

Oslo, Norway

RECRUITING

NextMove, NTNU

Trondheim, Norway

RECRUITING

St Olavs Hospital Stroke Unit

Trondheim, Norway

RECRUITING

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Axel Sandvig, PhD prof

    Norwegian University of Science and Technology

    PRINCIPAL INVESTIGATOR
  • Jorunn Helbostad, PhD prof

    Norwegian University of Science and Technology

    STUDY DIRECTOR
  • Bent Indredavik, PhD prof

    St. Olavs Hospital

    STUDY DIRECTOR

Central Study Contacts

Axel Sandvig, PhD ass prof

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 25, 2021

First Posted

October 20, 2021

Study Start

November 11, 2021

Primary Completion

February 1, 2024

Study Completion

February 1, 2024

Last Updated

November 30, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations